• 267 results in Exploration of Targeted Anti-tumor Therapy
    Sort by
    Most Cited
    Open Access
    Review
    Current strategies for the design of PROTAC linkers: a critical review
    PROteolysis TArgeting Chimeras (PROTACs) are heterobifunctional molecules consisting of two ligands; an “anchor” to bind to an E3 ubiquitin ligase and a “warhead”  [...] Read more.
    Robert I. Troup ... Matthias G. J. Baud
    Published: October 30, 2020 Explor Target Antitumor Ther. 2020;1:273–312
    DOI: https://doi.org/10.37349/etat.2020.00018
    This article belongs to the special issue Proteolysis Targeting Chimera (PROTAC)
    View:27134
    Download:3111
    Open Access
    Review
    The impact of tumour pH on cancer progression: strategies for clinical intervention
    Dysregulation of cellular pH is frequent in solid tumours and provides potential opportunities for therapeutic intervention. The acidic microenvironment within a tumour can promote migration, invasi [...] Read more.
    Carol Ward ... Simon P Langdon
    Published: April 28, 2020 Explor Target Antitumor Ther. 2020;1:71–100
    DOI: https://doi.org/10.37349/etat.2020.00005
    View:17178
    Download:717
    Open Access
    Review
    Diagnostic value of liquid biopsy in the era of precision medicine: 10 years of clinical evidence in cancer
    Liquid biopsy is a diagnostic repeatable test, which in last years has emerged as a powerful tool for profiling cancer genomes in real-time with minimal invasiveness and tailoring oncological decisi [...] Read more.
    Vincenza Caputo ... Stefania Napolitano
    Published: February 28, 2023 Explor Target Antitumor Ther 2023;4:102–138
    DOI: https://doi.org/10.37349/etat.2023.00125
    This article belongs to the special issue The Implementation of Liquid Biopsy in Clinical Practice for Different Solid Tumor
    Open Access
    Review
    Novel approaches for the rational design of PROTAC linkers
    Proteolysis targeting chimeras (PROTACs) represent a promising class of hetero-bivalent molecules that facilitate ubiquitination of a target protein by simultaneously binding and bringing together b [...] Read more.
    Almaz Zagidullin ... Emil Bulatov
    Published: October 30, 2020 Explor Target Antitumor Ther. 2020;1:381–390
    DOI: https://doi.org/10.37349/etat.2020.00023
    This article belongs to the special issue Proteolysis Targeting Chimera (PROTAC)
    View:6592
    Download:436
    Open Access
    Review
    The clinical advances of proteolysis targeting chimeras in oncology
    Proteolysis targeting chimeras (PROTACs) are a class of small molecules designed to target proteins for degradation. Their novel and unique modes of action provide PROTACs with the potential for the [...] Read more.
    Hao Xie ... Jason B. Fleming
    Published: December 31, 2021 Explor Target Antitumor Ther. 2021;2:511–521
    DOI: https://doi.org/10.37349/etat.2021.00061
    This article belongs to the special issue Proteolysis Targeting Chimera (PROTAC)
    View:4989
    Download:220
    Open Access
    Review
    Potential role of resveratrol and its nano-formulation as anti-cancer agent
    The uncontrolled and metastatic nature of cancer makes it worse and more unpredictable. Hence, many therapy and medication are used to control and treat cancer. However, apart from this, many medica [...] Read more.
    Akshay Kumar ... Dilpreet Singh
    Published: October 31, 2022 Explor Target Antitumor Ther. 2022;3:643–658
    DOI: https://doi.org/10.37349/etat.2022.00105
    This article belongs to the special issue Plant Extracts as an Infinite Resource for New Anticancer Agents
    Open Access
    Review
    Development of PROTACs to address clinical limitations associated with BTK-targeted kinase inhibitors
    Chronic lymphocytic leukemia is a common form of leukemia and is dependent on growth-promoting signaling via the B-cell receptor. The Bruton tyrosine kinase (BTK) is an important mediator of B-cell  [...] Read more.
    Rachael Arthur ... Graham Packham
    Published: June 29, 2020 Explor Target Antitumor Ther. 2020;1:131–152
    DOI: https://doi.org/10.37349/etat.2020.00009
    This article belongs to the special issue Proteolysis Targeting Chimera (PROTAC)
    View:7678
    Download:286
    Open Access
    Review
    New antibody-drug conjugates (ADCs) in breast cancer—an overview of ADCs recently approved and in later stages of development
    Antibody-drug conjugates (ADCs) have changed the treatment of breast cancer (BC) in more recent years. BC is a heterogenous group of malignancies with a broad range of histopathological characterist [...] Read more.
    Kira-Lee Koster ... Markus Joerger
    Published: February 24, 2022 Explor Target Antitumor Ther. 2022;3:27–36
    DOI: https://doi.org/10.37349/etat.2022.00069
    This article belongs to the special issue Antibody-Drug Conjugates
    Open Access
    Review
    PROTACs are effective in addressing the platelet toxicity associated with BCL-XL inhibitors
    BCL-XL is an anti-apoptotic protein that plays an important role in tumorigenesis, metastasis, and intrinsic or therapy-induced cancer drug resistance. More recently, BCL-XL has also been identified [...] Read more.
    Peiyi Zhang ... Guangrong Zheng
    Published: August 31, 2020 Explor Target Antitumor Ther. 2020;1:259–272
    DOI: https://doi.org/10.37349/etat.2020.00017
    This article belongs to the special issue Proteolysis Targeting Chimera (PROTAC)
    View:6364
    Download:304
    Open Access
    Review
    Potential of guggulsterone, a farnesoid X receptor antagonist, in the prevention and treatment of cancer
    Cancer is one of the most dreadful diseases in the world with a mortality of 9.6 million annually. Despite the advances in diagnosis and treatment during the last couple of decades, it still remains [...] Read more.
    Sosmitha Girisa ... Ajaikumar B. Kunnumakkara
    Published: October 30, 2020 Explor Target Antitumor Ther. 2020;1:313–342
    DOI: https://doi.org/10.37349/etat.2020.00019
    This article belongs to the special issue Targeting Transcription Factors for Cancer Therapy